Teva to Pay $512 Million to Resolve Provigil-Delay Lawsuit
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. will pay $512 million to resolve a class-action lawsuit accusing the drugmaker of conspiring to delay sales of generic versions of its sleep-disorder medicine Provigil, ending almost a decade of litigation.
Cephalon Inc., which Teva acquired in 2011, agreed to settle the antitrust case after a federal judge in Philadelphia refused this year to throw out purchasers’ claims that agreements between drugmakers to postpone release of generic medicines amount to anticompetitive behavior.